Pharmaceuticals - Diversified

Page 1

Spectrum Pharmaceuticals Inc Announces Additional Extension Of Tender Offer Period For Shares Of Allos Therapeutics, Inc.

Friday, 3 Aug 2012 07:05pm EDT

Spectrum Pharmaceuticals Inc and Allos Therapeutics, Inc. announced that Spectrum has provided an additional extension of the offer period in connection with tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any applicable withholding taxes. The extension was made in order for Spectrum and Allos to continue cooperating with the Federal Trade Commission (FTC) in relation to the previously announced Request for Additional Information and Documentary Material that each party received on May 9, 2012 from the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Allos by Spectrum. The offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on August 6, 2012, has been extended until 5:00 p.m., Eastern time, on August 20, 2012, unless extended for an additional period. All terms and conditions of the tender offer shall remain unchanged during the extended period.

FDA Approves Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for Metastatic Colorectal Cancer-Reuters

Friday, 3 Aug 2012 11:05am EDT

Reuters reported that the U.S. Food and Drug Administration has approved Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for use in combination with a folinic acid, fluorouracil and irinotecan chemotherapy regimen to treat adults with colorectal cancer.

Glaxosmithkline Plc Completes Acquisition Of Human Genome Sciences

Friday, 3 Aug 2012 02:00am EDT

Glaxosmithkline Plc announced that it has completed its acquisition of Human Genome Sciences for USD3.6 billion on an equity basis, or approximately USD3 billion net of cash and debt. All outstanding shares of HGS were acquired for USD14.25 per share in cash. Pursuant to the terms of the merger agreement, a wholly-owned subsidiary of GSK exercised its top-up option and, as the owner of more than 90% of the HGS outstanding common stock, subsequently completed a short-form merger with HGS. Each remaining share of HGS common stock not tendered (other than shares as to which holders properly exercise appraisal rights) was converted in the merger into the right to receive USD14.25 in cash, without interest and less any required withholding taxes. As a result, HGS common stock will cease to be traded on NASDAQ. Lazard and Morgan Stanley acted as financial advisors to GSK, and Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz provided legal advice to GSK.

Glenmark Pharmaceuticals Ltd Announces Demise of Chairman Emeritus

Thursday, 2 Aug 2012 08:30am EDT

Glenmark Pharmaceuticals Ltd announced that Mr. Gracias Saldanha, Founder and Chairman Emeritus of the Company passed away on July 21, 2012.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.